Radiopharmaceuticals for prostate cancer to go nuclear with $6.3 bn in sales by 2030
GlobalData analyst consensus forecast predicts the global revenue of Pluvicto to rise from $980 million in 2023 to $4.3 billion by…
Recover your password.
A password will be e-mailed to you.